Financial

Exactech Q1 Revenue Up 6% to $65.3 Million

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced revenue of $65.3 million for the first quarter of 2016, a 6% increase from $61.4 million in the first quarter of 2015. On a constant currency basis, revenue was up 7%. Net income was $4.4 million, or $0.31 per diluted share, compared to $4.1 million, or $0.29 per diluted share, in the same quarter a year ago.

First Quarter Segment Performance

The following are company revenue results, as well as adjusted revenue comparisons on a constant currency basis:

  • Extremity implant revenue increased 15% to $24.2 million, a 15% constant currency increase
  • Knee implant revenue increased 5% to $19.4 million, a 6% constant currency increase
  • Hip implant revenue increased 4% to $11.3 million, a 5% constant currency increase
  • Biologic and Spine revenue increased 5% to $5.4 million, a 7% constant currency increase
  • Other revenue decreased 13% to $5.0 million, a 12% constant currency decrease

Management Comment

Exactech CEO and President David Petty said, “Worldwide sales increased 6% to $65.3 million. U.S. sales were up 8% to $44.6 million compared with $41.2 million in the first quarter a year ago. International sales increased 3% to $20.7 million. U.S. sales represented 68% of total sales and international sales were 32% of the total. During the quarter we continued to do surgeries with our new revision hip and revision knee systems which remain in pilot launch mode. We will ramp up availability of both of those systems during the second and third quarters. The proximal humeral reconstruction stem is in full launch. We also are seeing increased benefit from improvements we have made to the U.S. sales channel and expect that momentum to continue.”

Chief Financial Officer Jody Phillips said, “Gross margins decreased to 69% from 70% for the first quarter a year ago due to continued pricing pressures. Total operating expenses for the quarter increased 5% to $38.6 million; however, as a percentage of sales decreased to 59%, compared to 60% for the first quarter of 2015. Sales and marketing expenses increased 7% to $23.3 million, which included the integration of our recently acquired distributor in Australia. General and administrative expenses increased 1% in the first quarter to $5.9 million and research and development expenses increased 12% to $5.1 million during the first quarter reflecting ongoing significant investment in our new product pipeline.

Looking forward, Exactech increased its 2016 revenue guidance to $250-$257 million and its diluted EPS target to $1.14 – $1.19. For the second quarter ending June 30, 2016, the company said it anticipates revenues of $63-$65 and diluted EPS of $0.29-$0.31. The foregoing statements regarding targets for the quarter and full year are forward-looking and actual results may differ materially. These are the company’s targets, not predictions of actual performance.

The financial statements are below.

Conference Call

The company will hold a conference call with CEO David Petty and key members of the management team on Wednesday, April 27that 10:00 a.m. Eastern Time. The call will cover Exactech’s first quarter 2016 results. Mr. Petty will open the conference call and a question-and-answer session will follow.

To participate in the call, dial 1-888-556-4997 any time after 9:50 a.m. Eastern on April 27th. International and local callers should dial 1-719-325-2464. A live webcast of the call will be available at http://www.hawkassociates.com/profile/exac.cfm orhttp://public.viavid.com/index.php?id=119078. This call will be archived for approximately 90 days.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com andhttp://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

EXACTECH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited) (audited)
March 31, December 31,
2016 2015
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 9,114 $ 12,713
Trade receivables, net of allowances of $1,075 and $1,011 54,763 52,442
Prepaid expenses and other assets, net 4,105 2,552
Income taxes receivable 389 486
Inventories, current 72,577 71,429
Total current assets 140,948 139,622
PROPERTY AND EQUIPMENT:
Land 4,515 4,494
Machinery and equipment 37,580 37,008
Surgical instruments 132,149 123,533
Furniture and fixtures 4,685 4,655
Facilities 21,368 20,348
Projects in process 1,218 1,218
Total property and equipment 201,515 191,256
Accumulated depreciation (100,584 ) (96,713 )
Net property and equipment 100,931 94,543
OTHER ASSETS:
Deferred financing and deposits, net 879 858
Non-current inventory 12,359 8,995
Product licenses and designs, net 11,047 11,121
Patents and trademarks, net 1,360 1,426
Customer relationships, net 644 92
Goodwill 22,561 18,850
Total other assets 48,850 41,342
TOTAL ASSETS $ 290,729 $ 275,507
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable $ 17,129 $ 13,932
Income taxes payable 2,296 603
Accrued expenses 11,104 9,498
Other current liabilities 2,851 792
Total current liabilities 33,380 24,825
LONG-TERM LIABILITIES:
Deferred tax liabilities 806 443
Long-term debt, net of current portion 16,000 16,000
Other long-term liabilities 6,255 5,850
Total long-term liabilities 23,061 22,293
Total liabilities 56,441 47,118
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Common stock 143 142
Additional paid-in capital 83,929 81,963
Treasury Stock (3,042 )
Accumulated other comprehensive loss, net of tax (9,414 ) (11,986 )
Retained earnings 162,672 158,270
Total shareholders’ equity 234,288 228,389
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 290,729 $ 275,507

EXACTECH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
(Unaudited)
Three Month Periods
Ended March 31,
2016 2015
NET SALES $ 65,298 $ 61,376
COST OF GOODS SOLD 20,368 18,642
Gross profit 44,930 42,734
OPERATING EXPENSES:
Sales and marketing 23,319 21,850
General and administrative 5,914 5,847
Research and development 5,070 4,529
Depreciation and amortization 4,324 4,442
Total operating expenses 38,627 36,668
INCOME FROM OPERATIONS 6,303 6,066
OTHER INCOME (EXPENSE):
Interest income 4 2
Other income 40 28
Interest expense (262 ) (302 )
Foreign currency exchange (loss) gain 494 (202 )
Total other expenses 276 (474 )
INCOME BEFORE INCOME TAXES 6,579 5,592
PROVISION FOR INCOME TAXES 2,177 1,480
NET INCOME $ 4,402 $ 4,112
BASIC EARNINGS PER SHARE $ 0.31 $ 0.30
DILUTED EARNINGS PER SHARE $ 0.31 $ 0.29
SHARES – BASIC 14,057 13,916
SHARES – DILUTED 14,173 14,174

Contacts

Exactech, Inc.
Investor contacts
Jody Phillips, 352-377-1140
Executive Vice President of Finance &
Chief Financial Officer
or
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
EXAC@hawkassociates.com
or
Media contact
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button